05 LLDAS is an excellent outcome measure, but does it really capture patients with true LDA?

Eric Morand
2022 Lupus Science and Medicine  
Learning Objectives . Describe the evidence base for current cyclophosphamidebased regimens . Discuss the advantages and disadvantages of using cyclophosphamide-based regimens . Explain how cyclophosphamide might be used in combination with newer therapies
doi:10.1136/lupus-2022-la.5 doaj:dbc1d254b53f469ba859e142a390b112 fatcat:v2elb3nnizaa7eznf3ilyovhie